Cargando…

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

BACKGROUND: Fifty percent of patients with muscle–invasive bladder cancer (MI-BC) die from their disease and current chemotherapy treatment only marginally increases survival. Novel therapies targeting receptor tyrosine kinases or activated oncogenes may improve outcome. Hence, it is necessary to st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kompier, Lucie C., Lurkin, Irene, van der Aa, Madelon N. M., van Rhijn, Bas W. G., van der Kwast, Theo H., Zwarthoff, Ellen C.
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2972209/ https://www.ncbi.nlm.nih.gov/pubmed/21072204 http://dx.doi.org/10.1371/journal.pone.0013821

Ejemplares similares

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
por: Lurkin, Irene, et al.
Publicado: (2010)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer
por: Takahashi, Naoki, et al.
Publicado: (2014)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS
por: Eijkelenboom, Astrid, et al.
Publicado: (2019)

Mutation status and prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese colorectal cancer patients
por: Guo, Fang, et al.
Publicado: (2018)

Mutational frequency of KRAS, NRAS, IDH2, PIK3CA, and EGFR in North Indian gallbladder cancer patients
por: Sharma, Aarti, et al.
Publicado: (2017)

KRAS, NRAS, BRAF, PIK3CA, and AKT1 signatures in colorectal cancer patients in south-eastern Romania
por: Brinzan, Costel Stelian, et al.
Publicado: (2022)

Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation
por: Zhao, Jidong, et al.
Publicado: (2021)

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas()()
por: Myers, Meagan B., et al.
Publicado: (2016)

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
por: Palomba, Grazia, et al.
Publicado: (2016)

KRAS , NRAS , BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
por: Mirzapoor Abbasabadi, Zohreh, et al.
Publicado: (2023)

Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases
por: Zhang, Jing, et al.
Publicado: (2015)

KRAS/NRAS Mutations Associated with Distant Metastasis and BRAF/PIK3CA Mutations Associated with Poor Tumor Differentiation in Colorectal Cancer
por: Zeng, Juanzi, et al.
Publicado: (2023)

Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma
por: Rieke, Damian T., et al.
Publicado: (2023)

PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma
por: Chiosea, Simion I, et al.
Publicado: (2013)

A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer
por: Kawazoe, Akihito, et al.
Publicado: (2015)

Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience
por: Baltruškevičienė, Edita, et al.
Publicado: (2016)

PIK3R1, HRAS and AR Gene Alterations Associated with Sclerosing Polycystic Adenoma of the Parotid Gland
por: Bahmad, Hisham F., et al.
Publicado: (2023)

Concomitant deletion of HRAS and NRAS leads to pulmonary immaturity, respiratory failure and neonatal death in mice
por: Fuentes-Mateos, Rocío, et al.
Publicado: (2019)

Argonaute 2 modulates EGFR–RAS signaling to promote mutant HRAS and NRAS-driven malignancies
por: Siebenaler, Ronald F, et al.
Publicado: (2022)

Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit
por: Bando, Hideaki, et al.
Publicado: (2013)

Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital
por: Harahap, Agnes Stephanie, et al.
Publicado: (2023)

Effectors of Epidermal Growth Factor Receptor Pathway: The Genetic Profiling of KRAS, BRAF, PIK3CA, NRAS Mutations in Colorectal Cancer Characteristics and Personalized Medicine
por: Shen, Yinchen, et al.
Publicado: (2013)

Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania
por: Afrăsânie, Vlad-Adrian, et al.
Publicado: (2023)

Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer
por: Wu, Jing-Bo, et al.
Publicado: (2023)

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

Selection of Microsatellite Markers for Bladder Cancer Diagnosis without the Need for Corresponding Blood
por: van Tilborg, Angela A. G., et al.
Publicado: (2012)

Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
por: Goriely, Anne, et al.
Publicado: (2009)

Pulmonary epithelial–myoepithelial carcinoma without AKT1, HRAS or PIK3CA mutations: a case report
por: Yanagawa, Naoki, et al.
Publicado: (2020)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Analysis of mutations in the PIK3CA and FGFR3 genes in verrucous epidermal nevus
por: Miranda, Ludmilla Queirós, et al.
Publicado: (2013)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status
por: Jenniskens, Josien C. A., et al.
Publicado: (2022)

Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer
por: Jing, Changwen, et al.
Publicado: (2018)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
por: Adams, Richard, et al.
Publicado: (2017)

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features
por: Byron, Sara A., et al.
Publicado: (2012)

Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines
por: Tilborg, A A G van, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_m49vtsf8lsht7fi8j5sprsr4fc